Alopecia Areata: What It Is, and the Newer Prescription Options

Written Sep 18, 2026Sources re-read Sep 24, 2026

General information — nobody clinical checked this

Nobody who works on this site holds a medical qualification, and it has never been past a clinician of any kind. Every grade on it is arithmetic on public documents, not a clinical opinion about anyone. Talk to a doctor or a dermatologist before starting, stopping or combining any treatment.

Diagnosis has to come first. Thyroid disease, low iron, alopecia areata, scarring alopecias, a medicine you are already taking and a heavy shed after illness or weight loss all thin hair, and none of them is pattern baldness — so none of them is fixed by a product bought for it. If you are not sure which you have, that is the first thing to ask, and what a dermatologist checks sets out what that appointment looks like.

Nothing on this page is a dose, a regimen or an instruction. How much of anything, how often and whether at all are decisions for a prescriber and the product’s own label.

Alopecia areata is not pattern baldness and is not treated like it. The American Academy of Dermatology describes it as an autoimmune disease in which the immune system mistakenly attacks hair follicles, and adds the fact that changes how the whole condition feels: that attack rarely destroys the follicle, so it is possible to regrow hair.

It can begin at any age, although the AAD says most people get it in their teens, twenties or thirties. The classic presentation is round, smooth patches of loss on an otherwise normal-looking scalp, and it can also affect the beard, the eyebrows and the rest of the body.

Why this sits on a pattern-baldness site at all

Because the first job of any hair-loss page is to say when it is not the page you need. If your hair is coming out in discrete round patches, nothing in the index of hair-loss treatments is aimed at what you have, and the two treatments at the top of it are approved for a different condition entirely. The other presentations that are not pattern loss sit alongside this one.

What changed in 2022

For decades the treatments used for alopecia areata were borrowed from elsewhere. That changed with a class of drugs called JAK inhibitors, which act on part of the signalling the immune system uses, and three of them now carry FDA approvals for severe alopecia areata:

Baricitinib, approved on 13 June 2022 for adults with severe alopecia areata — the first systemic treatment approved for the condition.
Ritlecitinib, approved on 23 June 2023 for severe alopecia areata in adults and adolescents twelve years and older.
Deuruxolitinib, approved on 25 July 2024 for adults with severe alopecia areata.

These are prescription medicines and nothing on this page is a recommendation to take one. What they change is that the conversation with a dermatologist now has approved options in it.

What the trials actually showed

It is worth seeing the size of the effect rather than the headline, because "approved" and "works for most people" are different statements.

The FDA's own trial snapshot for ritlecitinib describes an efficacy trial of 718 patients. Its primary measure was the proportion of patients reaching a SALT score of 20 or less at week 24 — that is, 20% or less of the scalp still losing hair — and the result was 23.0% of treated patients against 1.6% on placebo. On the stricter measure of a SALT score of 10 or less, it was 13.4% against 1.5%.

That is a real difference and an honest one: roughly one in four reached the primary target in half a year, against almost nobody on placebo. It is also a long way from everybody, and trials of this class enrolled people with severe disease — the deuruxolitinib programme, for instance, enrolled patients with at least 50% scalp hair loss for more than six months.

Words you will meet

SALT score. The Severity of Alopecia Tool measures how much of the scalp has lost hair. A SALT score of 20 means a fifth of the scalp is affected, so a lower number is better, and trial results are usually reported as the proportion of people reaching a threshold rather than as an average.

Severe. In this context it is a threshold for entering a trial and for an approval, not a description of how distressing the condition is. The deuruxolitinib programme enrolled people with at least half the scalp affected for more than six months; someone with a single patch is outside that definition and still has alopecia areata.

Systemic. These medicines act throughout the body rather than on a patch of skin, which is the source of both the effect and the warnings.

Remission and relapse. The condition can improve without treatment and return after long stable periods, which makes any single before-and-after account — including a good one — a poor guide to what a treatment did.

The safety side is not small print

JAK inhibitors suppress part of the immune response, and the risks named on these products reflect that. The FDA's snapshot for ritlecitinib lists serious infections, malignancies, blood clots, allergic reactions and abnormal laboratory findings including low lymphocytes, low platelets and raised muscle and liver enzymes; common adverse events included headache, diarrhoea, acne, rashes, eczema, fever and mouth ulcers.

This is the reason these medicines are prescribed and monitored rather than bought, and the reason the decision involves weighing a condition that is not physically dangerous against treatments that carry real risk. That weighing is personal, and it belongs in a consulting room.

What else is used

Alopecia areata has long been treated with approaches that predate the approvals — corticosteroids in various forms, and other immune-directed treatments — and for limited patches some people choose to do nothing at all, because the condition can remit on its own. Which of those applies depends on how much hair is involved, how long it has been going on, age, and what the person wants, and none of it can be worked out from a web page.

What can be said here is the thing the AAD says: the attack rarely destroys the follicle, so regrowth remains possible even after a long time. That is a materially different situation from pattern baldness, where the process is gradual and does not turn itself around, and it is why the right first step is a diagnosis rather than a purchase.

Getting it diagnosed

A dermatologist recognises alopecia areata clinically in most cases, and the AAD mentions blood tests for thyroid disease and for iron and vitamin levels in the context of this condition, because it sits alongside other autoimmune conditions more often than chance would suggest. A scalp biopsy settles unclear cases.

If you are looking at a round, smooth patch, that appointment is the entire advice on this page. What the visit involves covers the rest.

Alopecia areata, briefly

What is the difference between alopecia areata and male pattern baldness?

Alopecia areata is autoimmune: the immune system attacks hair follicles, usually producing round, smooth patches that can appear at any age. Male pattern baldness is hormonal and gradual, follows a recognised shape at the temples and crown, and takes years. They have different causes, different treatments and different outlooks — the AAD notes that the autoimmune attack rarely destroys the follicle, so regrowth is possible.

Is there an approved treatment for alopecia areata?

Yes, for the severe form. The FDA approved baricitinib in June 2022 for adults, ritlecitinib in June 2023 for adults and adolescents from twelve, and deuruxolitinib in July 2024 for adults. All three are JAK inhibitors, all are prescription-only, and all carry warnings that reflect the fact that they suppress part of the immune response.

How well do the new alopecia areata drugs work?

The FDA's trial snapshot for ritlecitinib reports that 23.0% of treated patients reached the primary target of 20% or less scalp hair loss at week 24, against 1.6% on placebo, with 13.4% against 1.5% on the stricter measure. That is a clear difference from placebo and it is also a long way from everyone, in a trial that enrolled people with severe disease.

Will alopecia areata come back?

It can. The condition is known to relapse and to remit, sometimes without treatment and sometimes after years of stability, which is one of the things that makes decisions about long-term medication difficult. That balance — an unpredictable condition against treatments with real risks — is exactly what a dermatologist is for.

Everything here is graded on the same two questions in the index of hair-loss treatments, and the condition itself is set out in male pattern baldness. Information only, and nobody medically qualified has read it.